Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

Understanding the Burden and Impact of Financial Toxicity in Bladder Cancer: A Mixed Methods Study of 2 Diverse Patient Populations

Funder: Bladder Cancer Advocacy Network

Funding period
USD 50 K
Funding amount
Abstract
Background: Financial toxicity (FT) is reported by up to 50% of cancer survivors and is associated with decline in HRQoL, delaying care and higher mortality. Early data in bladder cancer (BC) suggests the same. Existing data have largely focused on cohorts that have homogeneity in terms of race/ethnicity, insurance type and socioeconomic status. No thresholds for FT in BC have been defined. Hypothesis: Our central hypothesis is that FT is highly prevalent in BC and impacts HR-QoL and treatment decisions. Our secondary hypothesis is that sociodemographic factors will impact the extent and type of FT that is experienced. Methods/Approach: 140 patients with existing BC diagnosis who are receiving treatment at a large, public hospital (site 1) and a tertiary cancer center (site 2) will be recruited to complete validated instruments of (1) financial toxicity/distress, (2) general and disease specific QoL, items pertaining to coping strategies including non-adherence. Clinicopathologic data will be collected from the medical record. 20 patients in each arm who were screened as having FT will undergo semi-structured interviews and this will be synthesized with quantitative data. Concurrent validity between the 2 validated FT measures will be performed and used to generate thresholds of FT associated with risk of decline in HRQoL and non-adherence. A focus group of 8 urologic bladder cancer experts followed by an exploratory survey of 100 urologists, medical oncologists and radiation oncologists will be conducted to assess provider awareness and attitudes. Applicability: FT is a critical factor in these PSN questions and thus necessitates thorough investigation: 1.How does a patient with invasive BC choose between preserving and removing the bladder? 2. How do we improve patient education about expectations for recovery and treatment success after radical cystectomy? 3. How can caregivers of patients with metastatic BC reduce their burdens?
Similar projects All >
Sorted by: Start Date
Project list item
Quantifying Risk and Resilience (R2) among Patients with Bladder Cancer: A Novel Personalized, Comprehensive Risk Stratification Program

Bladder Cancer Advocacy Network to Sarah Psutka, Jonathan Wright, Daniel Lin, John Gore, Ryan O'Malley, Anne Browning, Florian Fintelmann

USD 50,000
2020 - 2020
Project list item
Geriatric Conditions and Treatment Burden in Older Adults with Non-Muscle-Invasive Bladder Cancer and Their Caregivers

National Institute on Aging to TULLIKA GARG

USD 135,849
2019 - 2021
Project list item
Transdifferentiation of fibroblasts to urothelial progenitors for definitive urothelial replacement therapy in non-muscle invasive bladder cancer

Bladder Cancer Advocacy Network to Philip A Beachy, Kris Butalid Prado

USD 300,000
2019 - 2021
Project list item
Recombinant CCL2 as a novel treatment strategy for bladder cancer

Bladder Cancer Advocacy Network to Neelam Mukherjee, Robert Scott Svatek

USD 50,000
2019 - 2020

System

Categories
  • FOR (ANZSRC)

    1112 Oncology and Carcinogenesis

  • RCDC

    Mind and Body

  • RCDC

    Basic Behavioral and Social Science

  • RCDC

    Behavioral and Social Science

  • RCDC

    Cancer

  • RCDC

    Clinical Research

  • RCDC

    Patient Safety

  • RCDC

    Urologic Diseases

  • HRCS HC

    Cancer

  • HRCS RAC

    7.1 Individual care needs

  • Health Research Areas

    Health services & systems